← Human Trials & Peer-Reviewed Studies
A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
Plain-language guide to NCT07064486: phase 3 randomized trial of Semaglutide, 152 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT07064486
- Phase
- phase 3
- Status
- active, not recruiting
- Start
- 2025-07-04
- Completion (planned or actual)
- 2027-04-30
- Participants
- 152 (actual)
- Design
- randomized, open label (everyone knows who gets what), treatment
- Conditions studied
- Type 2 Diabetes (T2DM)
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
The trial (phase 3) is built around Semaglutide.
This trial is conducted in Indonesia.
It had three arms (groups): one (experimental), one (experimental) and one (active comparator).
The registry classes the interventions as drug.
Who Took Part
The registry lists 152 actual participants took part.
It was open to people of any sex aged from 18 years up to 75 years.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: ○ Have been diagnosed with type 2 diabetes mellitus (T2DM);. Have a BMI ≥23 kilograms per meter squared (kg/m²) at screening;.
The full record lists 5 inclusion and 8 exclusion criteria; among the exclusions: ○ previous diagnosis of type 1 diabetes, special type diabetes;; have the acute or chronic pancreatitis;; have a serious mental illness or speech impediment and be unable to fully understand the study;.
How the Study Was Run
It was run as a randomized, parallel-group and open-label study.
Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Groups ran in parallel: each of the participants stayed in one arm throughout.
Everyone knew when Semaglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.
It started in 2025-07-04 with completion listed for 2027-04-30.
It ran at 4 sites in Indonesia (4).
Its stated primary purpose is treatment.
What Was Measured
Primary outcome: Change From Baseline in Hemoglobin A1c (HbA1c) (time frame: Week 0 to Week 24).
It also tracked 5 secondary outcomes, for example Change From Baseline in Hemoglobin A1c (HbA1c), Change From Baseline in Body Weight and Change From Baseline in Fasting Serum Glucose.
What This Means in Plain Language
Put simply, this is a phase 3, randomized trial of Semaglutide in 152 people.
Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.